Our goal is to become a leading diagnostic player within selected neurodegenerative diseases through the development of the unique BCX compounds. BioChromix current focus is in vitro and in vivo diagnostics of Alzheimer’s disease. Alzheimer’s disease affects nearly 1 % of the world population. It is a progressive, degenerative, irreversible disease, and the most common form of dementia. The only reliable diagnosis of Alzheimer’s disease that we have today is post mortem identification of the disease in the brain. The Company's vision is to offer products that enable optimal drug development, patient selection in clinical trials and early disease detection. Main products in development: 1. World class molecular imaging of Alzheimer’s disease (AD) 2. Breakthrough in vitro assays and diagnostics analyzing the oligomeric Amyloid-β (Aβ) biomarker for AD The company protects its technology through an extensive patent portfolio. For more information please visit: www.biochromix.com
View Top Employees from BioChromix ABWebsite | http://www.biochromix.com |
Revenue | $424.2 million |
Employees | View employees |
Founded | 2004 |
Address | 2 Scheeles Väg, Solna, Stockholm, SE |
Phone | +46 70 949 17 21 |
Technologies |
JavaScript,
HTML,
PHP
+2 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering |
SIC | SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 873 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 54 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular BioChromix AB employee's phone or email?
The BioChromix AB annual revenue was $424.2 million in 2024.
BioChromix AB is based in Solna, Stockholm.
The NAICS codes for BioChromix AB are [541, 32, 54, 3254, 325].
The SIC codes for BioChromix AB are [87, 283, 873, 28].